Future oncology (London, England) · 2026
Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fuldeore Rupali, Amaefule Adaeze Q, Georgieva Gergana, Kimura Tomomi, Jiang Baoguo, Yu Kenneth H
Аннотация
AIM: To assess healthcare resource utilization (HRU) and costs among patients with metastatic pancreatic cancer (mPC).
PATIENTS AND METHODS: Adult US patients with an mPC diagnosis based on index date 1 January 2020-31 December 2022 were identified in the Merative MarketScan database. All-cause healthcare visits and costs (USD) were estimated per-person-per-month (PPPM) for 1 year post-index period. First-line (1L) treatments (≤90 days post-index) were categorized as FOLFIRINOX (leucovorin, fluorouracil, irinotecan, oxaliplatin)-based, gemcitabine+paclitaxel-based, other, or none.
RESULTS: Claims from 2318 patients with mPC were included: 68.6% (1589/2318) with commercial and 31.4% (729/2318) with Medicare. Mean total costs PPPM were $34,215 with commercial and $15,158 with Medicare. A total of 25.7% (409/1589) of commercially insured patients and 43.2% (315/729) of Medicare-insured patients did not receive 1L treatment. Median (interquartile range) cumulative length of stay was 0.8 days (0.1-2.4) with commercial insurance and 0.7 days (0.0-2.4) with Medicare. All-cause PPPM costs were higher for patients without 1L treatment than with 1L treatment in both insurance types, primarily driven by inpatient and outpatient visits.
CONCLUSIONS: Patients with mPC experienced high economic burden, mostly attributable to inpatient and outpatient costs. The high rate of patients with mPC not receiving 1L treatment merits further exploration.
PATIENTS AND METHODS: Adult US patients with an mPC diagnosis based on index date 1 January 2020-31 December 2022 were identified in the Merative MarketScan database. All-cause healthcare visits and costs (USD) were estimated per-person-per-month (PPPM) for 1 year post-index period. First-line (1L) treatments (≤90 days post-index) were categorized as FOLFIRINOX (leucovorin, fluorouracil, irinotecan, oxaliplatin)-based, gemcitabine+paclitaxel-based, other, or none.
RESULTS: Claims from 2318 patients with mPC were included: 68.6% (1589/2318) with commercial and 31.4% (729/2318) with Medicare. Mean total costs PPPM were $34,215 with commercial and $15,158 with Medicare. A total of 25.7% (409/1589) of commercially insured patients and 43.2% (315/729) of Medicare-insured patients did not receive 1L treatment. Median (interquartile range) cumulative length of stay was 0.8 days (0.1-2.4) with commercial insurance and 0.7 days (0.0-2.4) with Medicare. All-cause PPPM costs were higher for patients without 1L treatment than with 1L treatment in both insurance types, primarily driven by inpatient and outpatient visits.
CONCLUSIONS: Patients with mPC experienced high economic burden, mostly attributable to inpatient and outpatient costs. The high rate of patients with mPC not receiving 1L treatment merits further exploration.